Abstract
Ramucirumab (IMC-1121B, LY3009806) is a fully human G1 monoclonal antibody that specifically targets vascular endotelial growth factor receptor 2 (VEGFR-2) with a substantially greater binding affinity than that of its natural ligands. Early clinical trials in patients with advanced solid tumors demonstrated that biologically relevant blood target concentrations are achievable with tolerable doses, and also showed some preliminary evidence of clinical activity. Several pivotal phase III trials have now been concluded and have led regulatory agencies to grant marketing authorization to ramucirumab for use as second line therapy in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (as single agent or in combination with paclitaxel), in patients with advanced colorectal carcinoma (CRC) (in combination with infusional fluorouracil and irinotecan (FOLFIRI regimen)) and in patients with advanced non-small cell lung cancer (NSCLC) (in combination with docetaxel). In contrast, ramucirumab failed to significantly improve survival versus placebo as second line therapy in patients with advanced hepatocellular carcinoma (HCC). The aim of this review is to summarize the clinical development and emerging role of ramucirumab in gastrointestinal (GI) tumors, including relevant aspects of its mechanism of action, pharmacology, safety profile, and antitumor activity in gastric, HCC, and CRC carcinomas.
Similar content being viewed by others
References
Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–57.
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2006;9:669–76.
Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res. 2006;12:5018–22.
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.
Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–50.
Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733–40.
Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa mono therapy in patients with metastatic renal cell carcinoma: CALG 90206. J Clin Oncol. 2008;26:5422–8.
Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499–506.
Abdelrahim M, Konduri S, Basha R, et al. Angiogenesis: an update and potential drug approaches (review). Int J Oncol. 2010;36:5–18.
Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 1999;59:5209–18.
Posey JA, Ng TC, Yang B, et al. A phase I study of antikinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res. 2003;9:1323–32.
Miao HQ, Hu K, Jimenez X, et al. Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2. Biochem Biophys Res Commun. 2006;345:438–45.
Zhu Z, Hattori K, Zhang H, et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endhotelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia. 2003;17:604–11.
Lu D, Shen J, Vil MD, Zhang H, et al. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem. 2003;278:43496–507.
Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramcirumab (IMC-1121B), a fully human immunoglobulin G1monoclonal antibody targeting the vascular endothelial growth factor receptor 2. J Clin Oncol. 2010;28:780–7.
Chiorean EG, Hurwitz HI, Cohen RB, et al. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Ann Oncol. 2015;26(6):1230–7.
Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomized, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–9.
Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–35.
Tabernero J, Ohtsu A, Muro K, et al. Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer. J Clin Oncol 33, 2015 (suppl 3; abstr 121).
Al-Batran SE, Van Cutsem E, Oh SC, et al. RAINBOW: a global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: quality-of-life (QoL) results. J Clin Oncol. 2014;32:5s (suppl; abstr 4058).
Yoon HH, Bendell JC, Braiteh FS, et al. Ramucirumab plus FOLFOX as front-line therapy for advanced gastric or esophageal adenocarcinoma (GE-AC): randomized, double-blind, multicenter phase 2 trial. J Clin Oncol. 2014;32:5s (suppl; abstr 4004).
Fuchs CS, Tabernero J, Al-Batran SE, et al. A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophogeal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117). J Clin Oncol 33, 2015 (suppl; abstr TPS4131).
Zhu AX, Finn RS, Mulcahy M, et al. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line mono therapy in patients with advanced hepatocellular cancer. Clin Cancer Res. 2013;19:6614–23.
Zhu AX, Park JO, Ryoo BY, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following fist-line therapy with sorafenib (REACH): a randomized, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16:859–70.
Chau I, Peck-Radosavljevic M, Borg C, et al. Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study. J Clin Oncol 33, 2015 (suppl; abstr 4077).
Garcia-Carbonero R, Rivera F, Maurel J, et al. A phase II, open-label study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. Oncologist. 2014;19:350–1.
Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16:499–508.
Garcia-Carbonero R, Obermannova R, Bodoky G, et al. Quality-of-life results from RAISE: Randomized, double-blind phase III study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal carcinoma after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine [abstract no. O-020]. 17th World Congress on Gastrointestinal Cancer, Barcelona 2015.
Hochster HS, Catalano PJ, Mitchell EP, et al. A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC). J Clin Oncol 33, 2015 (suppl 3; abstr TPS793).
Kang JH, Lee SI, Lim H, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30:1513–8.
Iacovelli R, Pietrantonio F, Farcomeni A, et al. Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies. PLoS One. 2014;9:e108940.
Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14:29–37.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
RGC is partially funded by Fondo de Investigacion Sanitaria - Instituto de Salud Carlos III (PI10/02164, PI13/02295), Servicio Andaluz de Salud (PI-0259/2007) and RTICC-Instituto de Salud Carlos III (Spain) (R12/0036/0028).
Conflict of Interest
RGC has provided scientific advice to Lilly S.A. ASG and RGE declared no conflicts of interest.
Rights and permissions
About this article
Cite this article
Sanchez-Gastaldo, A., Gonzalez-Exposito, R. & Garcia-Carbonero, R. Ramucirumab Clinical Development: an Emerging Role in Gastrointestinal Tumors. Targ Oncol 11, 479–487 (2016). https://doi.org/10.1007/s11523-016-0419-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11523-016-0419-8